DS5 vs Cardiogen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Half-Life
- Estimated 30-60 minutes (peptide degradation)
- Short (minutes); gene-regulatory effects persist longer
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200-500 mcg per dose
- 10 mg per day
- Frequency
- Once nightly
- Daily for 10–30 days
- Key Benefits
- Promotes delta-wave (deep) sleep and improves sleep quality
- May reduce sleep onset latency
- HPA axis modulation for stress reduction
- Non-addictive sleep support without tolerance development
- Potential circadian rhythm normalization
- Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Side Effects
- Generally well-tolerated in research subjects
- Possible morning grogginess at higher doses
- Mild blood pressure fluctuations reported with DSIP
- Limited human safety data for DS5 specifically
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Stacks With
- —
- —